OnKure Therapeutics’ Post

In this latest K-Cast series, “Advancing Healthcare With Prescription Drug Therapeutics,” Masha Salsabili, PharmD, PhD offers insights on the future of prescription digital therapeutics (PDTs) and how the landscape might evolve for PDTs over the next 5 years. Watch the series here: https://bit.ly/4dR4oLW #ManagedCare #HealthTech

Arecor Therapeutics plc (AIM:AREC) Chief Business Officer Manjit Rahelu speaks to Thomas Warner from Proactive after the #biopharmaceutical group announced a significant development from its Specialty Hospital division. A new collaboration with an unspecified "global medical products company" will focus on reformulating a blockbuster #oncology drug into a ready-to-use liquid form, enhancing its efficiency and ease of use for patients. This marks a significant shift from its powdered form, which was complex and time-consuming to prepare. The reconstituted drug is not only more convenient but also aims to reduce waiting times for patients, thereby improving overall healthcare delivery. Dr. Rahelu highlighted the collaborative effort involving a global partner with expertise in R&D, manufacturing, commercialisation, and regulatory affairs. This partnership aims to leverage both entities' strengths, combining Arecor's innovative in-house development with the partner's global capabilities. Arecor's technology has been instrumental in this advancement, underscoring their capability to apply their technology across various therapeutic areas beyond diabetes. This development is the second major outcome from Arecor's in-house pipeline and Rahelu says it demonstrates Arecor's ability to independently identify and develop promising candidates, translating R&D efforts into value-driving collaborations. Watch at #Proactive #ProactiveInvestors #AIM #AREC #ArecorTherapeutics #Arecor https://ow.ly/Gh0o50Qfo5k

Spasticity Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spasticity pipeline constitutes 20 key companies continuously working towards developing 20 Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Pomerantz recently scored a major victory, overcoming in part a motion to dismiss its case against Y-mAbs Therapeutics, Inc., an #antibody therapy developer. According to the complaint, Y-mAbs failed to disclose to investors that the FDA had repeatedly advised the company that the effectiveness of the company's omburtamab therapy could not be reliably measured by the two studies it submitted, and therefore could not justify #FDA approval. Further, when its FDA application was denied, Y-mAbs allegedly told investors that the FDA merely wanted additional information, assuring investors that there would be no problem obtaining FDA approval. In October 2022, the FDA publicly released the three key issues with the application submitted by Y-mAbs and informed investors that the FDA Advisory Committee had voted unanimously that it could not approve the omburtamab therapy based on the submitted application. This news resulted in significant investor losses when Y-mAbs' share price plummeted. #SecuritiesLaw #InstitutionalInvestors #SecuritiesLitigation

Spasticity Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spasticity pipeline constitutes 20 key companies continuously working towards developing 20 Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Timothy O’Shea, MS, PharmD, discusses the role of evidence-based recommendations around biosimilars and unbranded biologics for increasing patient care, plus how payers and providers evaluate biosimilars through clinical data across multiple indications. Watch here: https://bit.ly/48OFbz5 Timothy O'Shea

Check out the pathways that 35 digital therapeutics took to reach patients, including their FDA review timelines, key milestones, and supporting evidence! In our comprehensive report we cover the FDA regulatory pathway taken by all major digital therapeutic products approved / cleared within the last 12 years. Let us know if you'd like to discuss further! #digitalhealth #medicaldevices #medtech

Continued Emphasis on the Brain Disease Model: Despite its limitations, the brain disease model continues to dominate largely because it supports the development and funding of medical treatments and pharmaceutical interventions, which are concrete, scalable, and economically beneficial for the medical and pharmaceutical industries. Additionally, this model has played a significant role in shaping public policies and research agendas. #Addiction #Recovery